CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company’s commitment to advancing Ampligen® for patients with pancreatic cancer Access it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Recent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transformative 12-Month Value Creation Opportunity OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Live webcast on Wednesday, June 24th at 2:40 PM ET OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026. Details for the presentation are as follows: Date and Time:...
Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today announced that it has received written notice from the NYSE American that AIM has regained...
OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million, before deducting...
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral research Discussion highlights Ampligen’s immune-modulating mechanism, prior Biosafety Level 4 findings and potential applicability across emerging viral threats New Ebola-focused corporate presentation...
Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Investor “Ebola: What This Means” Segment on June 4 th at 9:00 AM ET OCALA, Fla., May 27, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the “Common Stock”) (or common...
Increase in stockholder equity and note extension strengthen Company’s ability to advance pancreatic cancer development strategy OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consultant for AIM ImmunoTech, is now available on demand here OCALA, Fla., May 14, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc....
OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class...
Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
Company to participate in Live Virtual Investor Closing Bell segment today, April 16 th at 4:00 PM ET ; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025, contained an audit report from its independent registered public accounting firm with a going concern emphasis of matter....
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16 th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K....
AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today...